Market closed

MannKind/$MNKD

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About MannKind

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Ticker

$MNKD
Trading on

Industry

Biotechnology

Employees

413

MannKind Metrics

BasicAdvanced
$2B
Market cap
89.30
P/E ratio
$0.08
EPS
1.30
Beta
-
Dividend rate
$2B
1.3
$7.39
$3.17
2.2M
4.545
3.839
-159.239
-165.16
1.60%
9.12%
-9.34%
89.301
7.208
-9.3
-8.99
66.702
51.35%
-166.03%
48.64%
-37.41%

What the Analysts think about MannKind

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for MannKind stock.

MannKind Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MannKind Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MNKD

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for MannKind stock?

MannKind (MNKD) has a market cap of $2B as of November 14, 2024.

What is the P/E ratio for MannKind stock?

The price to earnings (P/E) ratio for MannKind (MNKD) stock is 89.3 as of November 14, 2024.

Does MannKind stock pay dividends?

No, MannKind (MNKD) stock does not pay dividends to its shareholders as of November 14, 2024.

When is the next MannKind dividend payment date?

MannKind (MNKD) stock does not pay dividends to its shareholders.

What is the beta indicator for MannKind?

MannKind (MNKD) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.